Identification of the Pla2 Responsible For Prostanoid Synthesis in Response to Inflammatory Cytokines by Fernando, Chaminda
Masthead Logo
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2005
Identification of the Pla2 Responsible For
Prostanoid Synthesis in Response to Inflammatory
Cytokines
Chaminda Fernando
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Biochemistry, Biophysics, and Structural Biology Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/803
O Charninda Fernando 2005 
All Rights Reserved 
. . . 
111 
IDENTIFICATION OF THE PLA;! RESPONSIBLE FOR PROSTANOID SYNTHESIS 
IN RESPONSE TO INFLAMMATORY CYTOKINES 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
by 
CHAMINDA FERNANDO 
Bachelor of Science, University of Maryland, College Park, 2001 
Director: CHARLES E. CHALFANT, Ph.D. 
ASSISTANT PROFESSOR 
DEPARTMENT OF BIOCHEMISTRY 
Virginia Commonwealth University 
Richmond, Virginia 
August, 2005 
Acknowledgements 
I would like to extend my heartfelt appreciation and thanks to my mentor and 
advisor, Dr. Charles Chalfant, for his guidance, enthusiasm, and great sense of humor. 
I would also like to thank all the members of the Chalfant lab, the greatest group of 
people anyone could ask for. 
Thank you to my committee members, Dr. George Ford and Dr. Mohammed 
Kalimi, for their advice and guidance since the time I started the certificate program. 
Last, but not least, thank you to my family for their unconditional love and support, 
which has made all of this possible. 
Table of Contents 
Page 
. . List of Tables ..................................................................................................................... vll 
. . . List of Figures .................................................................................................................. vill 
. . List of Abbreviations .......................................................................................................... ix 
Abstract ............................................................................................................................... x 
Chapter 
1 Introduction ....................................................................................................... 1 
2 Materials and Methods ............. ............ ... . ..... ... .. . ................ . . . . . . . . . 15 
2.1 Maintenance of A549 Human Adenocarcinoma Cells ......................... 15 
2.2 siRNA Transfection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 
2.3 Treatment with Cytokines . ... .. ....... .. ... .. ...... .. .. ... .. .. .. . . . . . ......... . . 17 
2.4 WST-1 Assay ........................................................................................ 17 
2.5 Enzyme Linked immuno Sorbent Assay (ELISA) ............................... 17 
2.6 Western Immunoblotting Against cPLA2a ........................................... 19 
3 Results ............................................................................................................. 21 
3.1 Optimization of the Media Used in the Transfection of A549 Cells with 
siRNA ....... ... .. ....... .......... .. ... .... .. . . . . . . . . . . . . . . . . . . . . . . . 21 
3.2 Optimization of the Transfection Protocol for siRNA ......................... 24 
3.3 Optimization of the Stable Maintenance of PGE2 Production in A549 
Cells ...................................................................................................... 24 
3.4 cPLA2a siRNA Down Regulates Target Protein ................................. 25 
vi 
3.5 cPLA2a Regulates PGE2 Generation at Basal Levels and In Response to 
....................................................................... Inflammatory Cytokines 25 
3.6 cPLA2y, cPLA26, and iPLA2 regulate the basal levels of PGE2 production 
...... and cPLA2p is not involved in prostanoid synthesis in A549 cells 26 
4 Discussion ....................................................................................................... 31 
References ......................................................................................................................... 35 
Vita .................................................................................................................................... 39 
vii 
List of Tables 
Page 
Table 1: Classification of Phospholipases. ......................................................................... 9 
viii 
List of Figures 
Page 
Figure 1: Prostaglandin Biosynthesis is Carried Out by Most Cells of the Body ............... 4 
...................................................................................... Figure 2: Eicosanoid Biosynthesis 5 
Figure 3: Hydrolysis of Membrane Phospholipids ............................................................. 7 
Figure 4: Structure of PLA2 Isoforms ............................................................................... 11 
Figure 5: C- 1.P. the "Missing Link" in Inflammatory Agonist Mediated Eicosanoid 
....................................................................................................... Biosynthesis 13 
....................... Figure 6: Optimized Protocol Used to Transfect A549 Cells with siRNA 22 
Figure 7: Transferring the Media Collected from the Cytokine Treated Cells on to an 
ELISA Plate to Quantitate PGE2 ........................................................................ 23 
Figure 8: Down Regulation of cPLA2a by RNAi Transfection ........................................ 27 
Figure 9: Down Regulation of PLA2 Isoforms Using RNAi Transfection Resulted in 
Decreased PGE2 Production .............................................................................. 28 
Figure 10: Down Regulation of cPLA2P has no Effect on PGE2 Production ................... 30 
List of Abbreviations 
AA 
ATCC 
C-1-P 
CaLB 
COX 
cPLA2 
ELIS A 
IL-1s 
iPLA2 
NSAIDS 
PAF 
PGE2 
RNAi 
SIC 
siRNA 
SMase D 
sPLA2 
TNFa 
Arachidonic acid 
American Type Culture Collection 
Ceramide-1-phosphate 
Calcium Dependent Lipid Binding Domain 
Cyclooxygenase 
Cytosolic Phospholipase A2 
Enzyme Linked Immuno Sorbent Assay 
Interleukin-1 beta 
Calcium independent Phospholipase A2 
Non-Steroidal Anti-Inflammatory Drugs 
Platelet Activating Factor 
Prostaglandin E2 
RNA interference 
Standard Incubator Conditions 
small interfering RNA 
Sphingomyelinase D 
secreted Phospholipase A2 
Tumor Necrosis Factor-alpha 
Abstract 
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Preliminary studies from our laboratory showed that cPLA2a may be responsible 
for approximately 50-60% of the PGE2 production in response to inflammatory cytokines. 
Thus, we hypothesized that a closely-related PLA2 is responsible for 40-50% of the PGE2 
produced in response to inflammatory cytokines. To this end, we utilized RNAi 
technology, extensively optimized, to down regulate the expression of closely-related 
isoforms of phospholipase A2 in A549 cells and used an enzyme linked immuno sorbent 
assay (ELISA) to quantitate the PGE2 produced. These studies found that cytosolic 
phospholipase A2a (cPLA2a) regulated 97.7% of the prostaglandin E2 (PGE2) produced in 
response to inflammatory cytokines (e.g. IL-1P or TNFa), as well as regulating the basal 
levels of this prostanoid. Furthermore, cPLA2y, cPLA26, and iPLA2 were found to also 
xi 
regulate the basal levels of PGE2 production. On the other hand, cPLA2P was not involved 
in prostanoid synthesis in A549 cells either in the presence or absence of inflammatory 
cytokines. Thus, our studies show that cPLA2a plays the pivotal role in the production of 
PGE2 in response to inflammatory cytokines, and suggests that cPLA2a may be a possible 
drug target in diseases such as asthma, inflammation, and cancer. 
1. Introduction 
Inflammation is the first response of the immune system to infection or 
irritation. The symptoms of inflammation are characterized by rubor (redness), calor 
(heat), tumor (swelling), and dolor (pain), which have been known since the ancient times 
[I]. The study of the signal transduction pathway leading to inflammation has recently 
flourished due to the relationship of inflammation diseases to cancer, arteriosclerosis, and 
Alzheimer's disease [2-51. Recent studies have revealed that prostaglandins and 
leukotrienes operate as key intra- and inter-cellular inflammatory mediators. These 
bioactive lipids are produced as a result of the catalytic activity on arachidonic acid (AA) 
by cyclooxygenases (COX) to produce prostaglandins and by lipoxygenases to produce 
leukotrienes [6]. Initially, it was thought that the AA cascade was a constitutively active 
pathway generating prostaglandins for homeostatic functions such as maintenance of the 
renal blood flow and protection of the gastric lining [7]. This concept soon changed with 
the discovery of an inducible form of COX, COX-2, which led the former form of COX 
to be called COX-1; both of which are inhibited by aspirin and other forms of non- 
steroidal anti-inflammatory drugs [8]. Studies have shown that COX- 1 is responsible for 
basal level prostanoid synthesis and COX-2 is important in various inflammatory settings 
and cancer [8,9]. 
Prostaglandins were first isolated from semen in the 1930s, and it was thought 
that these bioactive lipids were synthesized in the prostate gland, hence the name 
prostaglandin. Since then many studies have shown that prostaglandins are produced in 
almost all the cells of the body and that they play a pivotal role in mediating disease 
states such as inflammation, thrombosis, diabetes, and cancer [lo]. They are also 
responsible for the promotion or inhibition of normal bodily functions such as 
vasodilation, blood clotting, ion transport, cell growth, lipolysis, and immune system 
response (figure 1). Prostaglandins belong to a subclass of lipids known as eicosanoids 
because of their structural similarities to the C-20 polyunsaturated fatty acids, the 
eicosanoic acids. Soon after the synthesis of prostaglandins, they are released from cells 
through facilitated transport and act in an autocrine or paracrine manner due to their short 
half lives (seconds to a few minutes) [8]. Therefore, prostaglandins must be synthesized 
as needed and are not stored free in tissues, and are one of the most potent natural 
substances known [I ,  111. The same prostaglandin can have different functions depending 
upon the receptor form on the surrounding cells [8]. Several types of prostaglandins are 
produced in the body based upon subtle differences in their structure and the most 
abundant COX-2 product is prostaglandin E2 (PGE2), and its levels are used as a measure 
of phospholipase activation. 
The binding of cytokines or growth factors to cell receptors or mechanical trauma 
can initiate a cascade of events leading to the activation of a group of very important 
enzymes known as the phospholipases. The hydrolysis of cell membrane lipids by 
phospholipases facilitates the release of AA, which is the precursor to prostaglandins and 
leukotrienes, from phospholipids, and this is the initial rate-limiting step in the eicosanoid 
biosynthetic pathways [12-151. The enzymes, COX-1 and COX-2, act on the released 
arachidonic acid to begin the prostaglandin synthetic pathway (Figure 2). 
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FIGURE 1. Prostaglandin biosynthesis is carried out by most cells of the body (FU 
D, Collin. Lipid Biology 2001,294: 1872) 
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FIGURE 2. Eicosanoid biosynthesis. Activated PLA2 releases arachidonic acid 
by hydrolysis of membrane phospholipids. Arachidonic acid can be utilized by either 
lipoxygenases to generate leukotrienes or by cyclooxygenases (COX-1 and COX-2) to 
generate the intermediate, PGG2 followed by PGH2. The activity of prostacyclin synthase, 
PGE synthase, PGD synthase, PGF synthase, and thromboxane synthase gives rise to 
prostaglandins and thromboxanes. 
Phospholipase A2 (PLA2) enzymes specifically catalyze the hydrolysis of the sn-2 
ester bond of phospholipids to release free fatty acids and lysophospholipids (Figure 3) 
[12,15,16]. Therefore, this group of enzymes plays a critical role in cellular lipid 
metabolism, thereby regulating energy storage, membrane remodeling, and the 
production of potent inflammatory mediators (e.g. prostaglandins and leukotrienes) in 
response to inflammatory cytokines such as IL- 1P and TNFa. 
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Figure 3. Hydrolysis of membrane phospholipids. Activated PLA2s cleaves 
membrane phospholipids at the sn-2 position to release arachidonic acid. The catalytic 
reactions of cyclooxygenases ultimately lead to the production of prostaglandins. The 
cyclooxygenases are inhibited by non-steroidal anti-inflammatory drugs (NSAIDS). 
Mammalian cells contain structurally diverse forms of PLA2, classified into 
groups I, 11, 111, IV, V, VI, VII, VIII, IX, X, XI, and XI1 (Table 1) [16,17]. Functionally, 
these groups are recombined into four types of PLA2s: secreted PLA2 (sPLA2), which are 
stored in cytosolic granules or synthesized upon stimulation and then secreted 
extracellularly, consisting of groups I, 11, 111, V, IX, X, XI, and XII; cytosolic PLA2 
(cPLA~), which are located in the cytosol and translocated into the membrane, consisting 
of groups IVA, IVB, IVC, and IVDelta; calcium independent PLA2 (iPLA2), which are 
located both in the cytosol and in membrane fractions, consisting of groups VIA, and 
VIB; and platelet-activating factor (PAF) acetylhydrolases consisting of groups VII 
and VIII [18-201. The cPLA2 family of phospholipases is further divided into four 
isoforms, cPLA2a (group IVA), cPLA2P (group IVB), cPLA2y (group IVC), and cPLA26 
(group IVDelta). 
Table 1. Classification of phospholipases. 
TY pe 
Secreted PLA2 
(sPLA2) 
Cytosolic PLA2 
(cPLA2) 
Calcium 
independent 
(iPLA2) 
Platelet Activating 
Factor (PAF) 
Acetylhydrolases 
The cDNAs of human PLA2 isoforms, cPLA2a, cPLA2P, cPLA2y, cPLA26, and 
iPLA2 encode polypeptides of 749, 1012, 541, 8 18, and 782 amino acids, respectively. 
Close examination of the primary structures of the group IV isoforms reveal sequence 
homology among the members, which can be related to the amino acid sequence of 
iPLA2 (figure 4). The mRNA for cPLA2 is widely expressed in the brain, lung, kidney, 
heart, and spleen [21-241. All 5 of the phospholipases contain two catalytic domains, A 
and B, with gene-unique sequences separating the domains. The amino acid residues that 
Group 
I, 11, 111, V, IX, X, 
XI, XI1 
IVA, IVB, IVC, 
IVDelta 
VIA, VIB 
VII, VIII 
Ca++ dependent 
binding to 
membranes 
- 
cPLA2a-Yes 
cPLA2P-Yes 
cPLA26-Yes 
cPLA2y-No 
No 
- 
Notes 
Stored in cytosolic 
granules or 
synthesized upon 
stimulation and then 
secreted 
extracellularly 
Located in cytosol 
and translocated 
into membrane, 
except for cPLA2y, 
which is membrane 
bound 
Located both in 
cytosol and 
membrane fractions 
- 
are important for catalytic activity of cPLA2a, Arg200, Ser228, Asp549, and Arg566, are 
all conserved in cPLA~P, cPLA2y, and cPLA26 [25-271. Mutagenesis studies have shown 
that amino acid residues Ser483 (catalytic domain A) and Asp627 (catalytic domain B) in 
iPLA2 are involved in catalytic activity and that these residues are homologous to Ser228 
and Asp549 in cPLA2a [ 181. 
Numerous findings on the structure of cPLA2a, cPLA2P, and cPLA26 have 
revealed that there is a 120 amino acid sequence near the N-terminus that encodes for the 
calcium-dependent lipid binding domain (C2lCaLB) [28-301. In cPLA2P and cPLA26 
there are 120 and 135 amino acid inserts, respectively, between the C2 domain and 
catalytic domain A. However, in cPLA2a, the C2 domain and the catalytic domain A are 
adjacent to each other. The C2lCaLB domain functions to facilitate the calcium- 
dependent binding of cPLA2a, cPLA2P, and cPLA26 to membranes. Studies have shown 
that calcium, at physiologically relevant concentrations, is required for the translocation 
of these cPLA2 isoforms from the cytosol to the cellular membranes. Numerous studies 
have revealed that calcium binding to the C2 domain functions as an electrostatic switch. 
Thus, calcium binding decreases the polarity on the surface of this domain by 
neutralizing negative charges and promotes penetration of hydrophobic residues into the 
membrane interior [24]. In contrast, cPLA2y is calcium-independent and is farnesylated at 
the C-terminus, which facilitate this enzyme to bind to membranes. 
Catalytic @ C ~ L B  Catalytic domain A ms515 domain B ~ 7 2 7  
Farnesylation 
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Figure 4. Structure of PLA2 isoforrns. All PLA2 isoforms carry 2 catalytic 
domains, A and B. The amino acid residues essential for catalytic activity, Arg200, 
Ser228, Asp549, and Arg566, are all conserved in cPLA2a, cPLA2P, cPLA2y, and cPLA26. 
In iPLA2, amino acid residues Ser483 in catalytic domain A and Asp627 in catalytic 
domain B are involved in catalytic activity. These residues are homologous to Ser228 and 
Asp549 in cPLA2a. The C2lCaLB domain found in cPLA2a, cPLA2P, and cPLA26 
facilitates the calcium dependent translocation of these enzymes to Golgilperinuclear 
regions. cPLA2y is membrane bound through farnesylation at the C-terminus. 
Research has shown that there is an essential component interacting with the 
CaLB domain of cPLA2, which can regulate the membrane association of cPLA2. 
Ceramide- 1 -phosphate (C-1-P), formed by the phosphorylation of ceramide by ceramide 
kinase is one such lipid regulator of cPLA2 and interestingly ceramide kinase has similar 
tissue distribution as cPLA2 (Figure 5) [11,22]. In other studies, the main component of 
the venom from the brown recluse spider, Loxosceles reclusa, is the enzyme 
sphingomyelinase D (SMase D) [11,3 11. SMase D is responsible for the hydrolysis of 
sphingomyelin to produce C-1-P and the bite of this spider causes an intense 
inflammatory response mediated by arachidonic acid and prostaglandins. This led our 
laboratory to hypothesize that C-1-P may function as a pathophysiologic link in the 
activation of cPLA2 and the inflammatory response mediated by arachidonic acid and 
prostaglandins and that there might be a mammalian counterpart to SMaseD, which led to 
the discovery of a biology for the enzyme, cerarnide kinase. 
INFLAMMATION - 
Figure 5. C-1-P, the "missing link" in inflammatory agonist mediated eicosanoid 
biosynthesis. Binding of inflammatory agonists to cell membrane receptors activates 
ceramide kinase resulting in the production of C-1-P, which goes on to activate cPLA2, 
cPLA2 hydrolyses membrane phospholipids to release arachidonic acid and this step can 
be inhibited by steroids. The released arachidonic acid is utilized by COX-2, which is 
inhibited by NSAIDS, to produce prostanoids ultimately resulting in inflammation. 
Published results from our laboratory establish ceramide kinase and subsequent 
C-1-P production as a "missing link" in eicosanoid biosynthesis in response to 
inflammatory agonists [11,22,23,]. This data is important because they revealed a specific 
biology regulated by C-1-P. In the same study, our laboratory showed that down- 
regulation of ceramide kinase decreased arachidonic acid release implicating that C-1-P 
is required for arachidonic acid release in response to inflammatory agonists [ I l l .  
Furthermore, C-1-P induced translocation of full-length cPLAz from the cytosol to the 
Golgi apparatuslperinuclear regions, and cPLA2 siRNA completely inhibited the 
induction of arachidonic acid release by C-1-P [ l  11. Unpublished findings disclose that 
cPLA2a is responsible for approximately 50-60% of the production of PGE2. Thus, we 
hypothesized that cPLA~P, cPLA2y, cPLA26, or iPLA2 are responsible for the remaining 
40-50% of the PGE2 production, and are possible targets for C- 1 -P. 
2. Materials and Methods 
2.1 Maintenance of A549 Human Adenocarcinoma Cells 
A549 cells, thawed from cultures stored in liquid nitrogen (freeze media: 10% 
sterile DMSO, 40% FBS, 50% supplemental media), were obtained from American Type 
Culture Collection (ATCC). The cells were grown in 250 mL canted, vented tissue 
culture flasks (Falcon) containing A549 culture media. This media is composed of 50% 
DMEM (Invitrogen) supplemented with L-glutamine, 50% 
RPMI 1640 (Invitrogen), 100 UIrnL of penicillin G sodium (Invitrogen), 100 pg1mL of 
streptomycin sulfate (Invitrogen), and 10% (vlv) heat inactivated fetal bovine serum 
(Invitrogen). Cell cultures were maintained at 37' C in a Heraeus incubator with 5% C 0 2  
(verified by gas analyzer) and 95% humidity (Standard Incubator Conditions (SIC)). For 
experiments, cells were counted using trypan blue dye and a hemocytometer (Fisher 
Scientific) and plated on 24-well plates at 1 . 2 5 ~ 1 0 ~  cells1mL per treatment. The 24-well 
plate was incubated overnight at SIC. 
2.2 siRNA Transfection 
The plate was observed under an inverted microscope the following day in order 
ensure that the cells were in the confluency range of 4.0-70% prior to siRNA transfection. 
The media was removed and each well was washed with 1 mL of Optimem (Invitrogen). 
Then, 200 pL of optimem were added to each well, and the plate was returned to SIC. 
The siRNA reagent, Dharmafect (Dharmacon), was prepared by diluting 2 pL of 
Dharmafect per treatment with 5.5 pL of optimem per treatment. This solution was 
incubated at room temperature for 10 minutes. siRNA (Dharmacon) 20pM stock 
solutions were made by adding 250 pL of 1X Dharmacon siRNA buffer to 5 nmol of 
lyophilized siRNA. Then, 2.5 pL per treatment of a respective siRNA stock solution was 
diluted in 40 pL per treatment of Optimem and the diluted Dharmafect was added to each 
siRNA solution at 7.5 pL per treatment. The solutions were mixed by pippeting up and 
down gently three times, and the siRNADharmafect complex was incubated at room 
temperature for 15-20 minutes. After the incubation period, the siRNADharmafect mix 
was added drop wise to the appropriate wells at 50 pL per well. The plate was swirled 
gently to mix well and then placed at SIC for 4 hours. Following the incubation period, 
125 pL of 3X growth media (1.8% Penicillin/Streptomycin, 30% Fetal Bovine Serum, 
68.2% Optimem) was added to each well and returned to standard incubation conditions 
for 24 hours. After the incubation period, A549 media was added to each well and the 
plate was gently swirled to mix, which was followed by removal of the media. 1 mL of 
A549 media was then added to each well, and the cells were returned to standard 
incubation conditions for 24 hours. 
2.3 Treatment with Cytokines 
On the day of the treatment, the cells were rinsed twice with resting media (2% 
Fetal Bovine Serum, 96.2% DMEM, 1.8% Penicillin/Streptomycin) and the cells were 
observed for any changes in confluency andfor morphology. The cytokines, IL-1P and 
TNFa were diluted in resting media at 5 ng/mL and 10 ng/mL, respectively. The media 
was removed and resting media with the appropriate cytokine was added to each well at 1 
mL per well. The control wells received equal amounts of PBS diluted in resting media 
(sham control). The plate was incubated at SIC. 
2.4 WST-1 Assay 
Following cytokine treatment, 750 pL of media from each well was collected. To 
the remaining 250 pL of media in the wells, 25 pL of WST-1 reagent (Roche 
Diagnostics) was added and the plate was placed back in the incubator for 30 minutes. 
After the incubation period, the optical density in each well of the plate was measured (at 
450 nM vs. a reference of 630 nM) using microplate spectrophotometer (BIO-TEK KC 
Junior). These data were used to normalize the proceeding PGE2 results. 
2.5 Enzyme Linked Immuno Sorbent Assay (ELISA) 
The standard was prepared by obtaining eight 1.5 mL microfuge tubes and 
numbering them #1 through #8. To tube #1, 180 pL of 1 in 40 dilution resting media in 
1X EIA buffer (Cayman Chemical) was added. To tubes #2 through #8, 100 pL of the 
same solution was added. Next, 20 pL of the standard PGE2 (Cayman Chemical) was 
added to tube #I and mixed thoroughly. In order to serially dilute the samples, 100 pL 
was removed from tube #1 and placed in tube #2 and mixed thoroughly, from tube #2 
100 pL was removed and placed in tube #3 and mixed thoroughly. This process was 
repeated until standard #8. The ELISA plate (Cayman Chemical), coated with goat anti- 
mouse IgG was loaded at 50 pL per well of standardlsample, where the sample was 
diluted at 1 in 40 (sample : 1X EIA), 50 pL of PGE2 EIA AChE tracer (Cayman 
Chemical), and 50 pL of PGE2 monoclonal antibody (Cayman Chemical). The control 
wells received 50 pL of 1X EIA buffer along with 50 pL of PGE2 EIA AChE tracer and 
50 pL of PGE2 monoclonal antibody. The plate was covered and placed in 4' C for 16 
hours. 
After the incubation period, all the liquid from the wells were removed and the 
plate was washed with wash buffer (Cayman Chemical) five times. Next, 200 pL of 
Ellman's reagent (Cayman Chemical) was added to each well and the plate was covered 
and allowed to develop in the dark with low shaking at room temperature for 90 minutes. 
Following the developing step, absorbance in each well at 405 nM was read using a 
microplate spectrophotometer (BMG Labtech FLUOStar Optima). Wells containing 
Ellman's reagent alone served as the blank for absorbance background. 
2.6 Western Immunoblotting Against cPLAza 
A549 cells were counted using trypan blue exclusion counting, and were plated 
into 6-well plates at 2 . 5 ~  10' cells135 mm well (4 mL total media) per treatment. The 6- 
well plate was incubated overnight at SIC. The plate was observed under an inverted 
microscope the following day in order ensure that the cells were in the confluency range 
of 40-70% prior to siRNA transfection. The media was removed and each well was 
washed with 1 mL of Optimem. Then, 600 pL of Optimem were added to each well and 
the plate was placed back in the incubator. Next, 7.5 pL per treatment of its respective 
siRNA 20 pM stock solution was diluted in 120 pL per treatment of Optimem. The 
siRNA reagent, Dharmafect (Dharmacon), was prepared by diluting 6 pL of Dharmafect 
per treatment with 16.5 pL of optimem per treatment. This solution was incubated at 
room temperature for 10 minutes. Then, the diluted Dharmafect was added to each 
siRNA solution at 22.5 pL per treatment. The solutions were mixed by pippeting up and 
down gently three times. These siRNA1Dharmafect complexes were incubated at room 
temperature for 15-20 minutes. After the incubation period, the siRNA/Dharmafect mix 
was added drop wise to the appropriate wells at 150 pL per well. The plate was swirled 
gently to mix well and then placed at SIC for 4 hours. Following the incubation period, 
375 pL of 3X growth media was added to each well, and the plate was returned to SIC for 
24 hours. On the following day, the cells were observed for any changes in confluency 
andlor morphology. Then, 1 mL of A549 media was added to each well and the plate was 
gently swirled to mix. Next, the media was removed, and 1 mL of A549 media was added 
to each well. The plate was returned to SIC for an additional 24 hours. After 24 hours, the 
cells were lifted using a cell lifter, and the media with the cells were transferred into 15 
mL conical tubes. The tubes were centrifuged at 4' C under low speed in order to pellet 
the cells, and the supernatant was discarded. The cell pellet was washed with 1X cold 
PBS and the tube was centrifuged again. The supernatant was discarded, and the cell 
pellet was re-suspended in 100 pL of 1X cold PBS and transferred to 1.5 mL microfuge 
tubes with screw caps. Next, 100 pL of 2X lysis buffer (200 p.L 1X Binding buffer, 10 pL 
Leupeptin, 1 pL Aproprotinin, 5 pL Pepstatin, 10 pL PMSF, 100 pL Glycerol) was 
added to the tubes, and the samples were boiled for 10 minutes. 
30 pL of the total protein lysate was subjected to 10% SDS-PAGE. Proteins were 
transferred to polyvinylidene difluoride membrane (Bio-Rad) and blocked in 5% milk, 
1 x PBS-T (M-PBS-T) for 2 h. The membrane was incubated with anti-cPLA2a poly- 
clonal goat IgG (Santa Cruz Biotechnology) or anti-a-tubulin mouse mono-clonal IgM 
(Santa Cruz Biotechnology) for 2 h in M-PBS-T followed by 3 washes with PBS-T. The 
membrane was then incubated with a secondary antibody of horseradish peroxidase- 
conjugated affinipure donkey anti-goat IgG (anti-cPLA2a) (Jackson Imrnuno Research 
Labs Inc.) or horseradish peroxidase-conjugated anti-mouse IgM (Cal-Biochem) (anti-a- 
tubulin) for 45 min followed by 3 washes with PBS-T. Immunoblots were developed 
using Pierce ECL reagents and Bio-Max film. 
3. Results 
3.1 Optimization of the media used in the transfection of A549 cells with siRNA 
Initially, we used DMEM as the media to wash the cells prior to transfection and 
to incubate the cells that have been transfected with siRNA. We observed that most of the 
cells in the center of the wells died just 24 hours post-transfection. Evidently, DMEM 
proved to be toxic to RNAi transfected cells. Then, we replaced the DMEM with 
optimem for the washing and incubation steps and the cell survival rate increased 
dramatically. Thus, optimem was used as the media of choice in the transfection of A549 
cells with siRNA. 
simA 24-well plate 
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Figure 6. Optimized protocol used to transfect A549 cells with siRNA 
J V 
96-well ELISA Plate 
Figure 7. Transferring the media collected from the cytokine treated cells on to an 
ELISA plate to quantitate PGE2. 
3.2 Optimization of the transfection protocol for siRNA 
During the initial stages of the project, we were using Oligofectamine transfection 
reagent (Invitrogen) to introduce siRNA to A549 cells. This protocol generated very good 
results until the manufacturer changed the reagent, causing non-reproducible results. We 
examined Dharmafect, the RNAi transfection reagent manufactured by the same 
company that produces siRNA, as a vehicle to introduce siRNA into A549 cells. This 
transfection reagent worked very effectively to generate reproducible results, and 
Dharmacon siRNA transfection protocol is the standard protocol now used by the 
Chalfant laboratory. 
3.3 Optimization of the stable maintenance of PGE2 production in A549 cells 
One of the obstacles that we had to overcome was the elevated basal levels of 
PGE2 production from the non-cytokine treated A549 cells. We attributed this to over 
stressing the cells. We incorporated a washout step with A549 complete media 24 hours 
post-transfection to overcome the elevated basal PGE2 production. This resulted in 
relatively low basal PGE2 levels. Thus, this step was incorporated into the siRNA 
transfection protocol. 
3.4 cPLA2a siRNA down-regulates target protein 
To determine if cPLA2a was downregulated by RNAi transfection, a Western 
immunoblot utilizing an anti-cPLA2a antibody was used. The normalized densitometry 
data indicated that cPLA2a was down-regulated by approximately 83% (figure 8). The 
data demonstrated that siRNA was specific to cPLA2a and that down-regulation of 
cPLA2a was not due to any off-target effects of siRNA. Furthermore, siRNA to the 
closely related cPLA26 and iPLA2 had no effect on cPLA2a levels, also demonstrating 
specificity. Therefore, the transfection was successful and cPLA2a siRNA actually down- 
regulated the target protein. 
3.5 cPLA2a regulates PGE2 generation at basal levels and in response to 
inflammatory cytokines 
Preliminary data from our laboratory inferred that cPLA2a may be responsible for 
approximately 50-60% of PGE2 production in response to inflammatory cytokines, but 
the RNAi technology was not optimized. To further verify this finding, and determine the 
percentage of PGE2 produced in response to inflammatory cytokines regulated by 
cPLA2a, RNAi transfection was again employed to down regulate the expression of 
cPLA2a. An optimized ELISA, to quantitate the PGE2 produced, specifically 
demonstrated that siRNA targeted to cPLA2a inhibited approximately 80% of the PGE2 
produced in response to either IL-1P or TNFa. Normalizing this percentage of inhibition 
to the percentage of down regulation of cPLA2a indicated that 96.4% of the PGE2 
produced in response to inflammatory cytokines was due to cPLA2a. Furthermore, 
siRNA targeted to cPLA2a inhibited 95.6% of the basal levels of PGE2 (figure 9). 
3.6 cPLA2y, cPLA26, and iPLA2 regulate the basal levels of PGE2 production and 
cPLA2p is not involved in prostanoid synthesis in A549 cells 
According to preliminary data, 50-60% of PGE2 produced in A549 cells in 
response to inflammatory cytokines was regulated by cPLA2a, thus we hypothesized that 
the remaining 40-50% is produced by cPLA2P, cPLA2y, cPLA26, or iPLA2. As stated 
above, optimization of the siRNA transfection demonstrated that approximately 100% of 
the PGE2 produced in response to inflammatory cytokines was due to cPLA2a. To further 
verify this finding, RNAi technology was utilized to down regulate the aforementioned 
PLA2 isoforms individually. cPLA2y, cPLA26, and iPLA2 inhibited the basal level of 
PGE2 production, but as expected these phospholipases had no effect on cytokine 
mediated production of PGE2 (figure 8). In addition to the above findings, the data 
indicated that cPLA2P did not have a role in the cytokine induced or the basal level of 
PGE2 production (figure 10). Therefore, these findings verify that cPLA2a is the PLA2 
responsible for PGE:! production in response to inflammatory cytokines as down 
regulation of closely related PLA2s had no effect. Furthermore, possible roles for iPLA2, 
cPLA2y cPLA26 in basal PGE2 synthesis have been implicated. 
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Figure 8. Down regulation of cPLA2a by RNAi transfection. Cells were transfected 
with respective siRNA and cell lysates were subjected to 10% SDS-PAGE analysis, 
transferred to a polyvinylidene difluoride membrane, and immunoblotted as described in 
"material and methods" section. The top panel shows the down regulation of cPLA2a in 
cells transfected with siRNA as compared to cells transfected with control, iPLA2, and 
cPLA26 siRNA. The bottom panel shows the blot normalized with a tubulin. 
Recombinant cPLA2a-V5-6XHis was used as positive control. This figure is 
representative of two independent experiments. 
Figure 9. Down regulation of PLA2 isoforms using RNAi transfection resulted in 
decreased PGE2 production. Cells were transfected with siRNA and treated with IL-1P 
(IL), TNFa (TNF), or PBS (-) as described in the "material and methods" section; Ctrl 
IL = transfected with control siRNA and treated with IL-1P; Ctrl TNF = transfected with 
control siRNA and treated with TNFa; Ctrl- = transfected with control siRNA and 
treated with PBS; Alpha IL = transfected with cPLA2a siRNA and treated with IL-1P; 
Alpha TNF = transfected with cPLA2a siRNA and treated with TNFa; Alpha- = 
transfected with cPLA2a siRNA and treated with PBS; Gamma IL = transfected with 
cPLA2y siRNA and treated with IL- 1 P; Gamma TNF = transfected with cPLA2y siRNA 
and treated with TNFa; Gamma- = transfected with cPLA2y siRNA and treated with 
PBS; Delta IL = transfected with cPLA26 siRNA and treated with IL-ID; Delta TNF = 
transfected with cPLA26 siRNA and treated with TNFa; Delta- = transfected with 
cPLA26 siRNA and treated with PBS; i IL = transfected with iPLA2 siRNA and treated 
with IL-1P; i TNF = transfected with iPLA2 siRNA and treated with TNFa; i- = 
transfected with iPLA2 siRNA and treated with PBS. This figure is representative of two 
independent experiments. 
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Figure 10. Down regulation of cPLA2$ has no effect on PGE2 production. Cells were 
transfected with siRNA and treated with IL-1P (+) or PBS (-) as described in the 
"material and methods" section; Ctrl + = transfected with control siRNA and treated with 
IL- 1 P; Ctrl- = transfected with control siRNA and treated with PBS; Beta + = transfected 
with cPLA2P siRNA and treated with IL-1P; Beta - = transfected with cPLAzP siRNA 
and treated with PBS. This figure is representative of two independent experiments. 
4. Discussion 
Unpublished findings from our laboratory disclosed that cPLA2a may be 
responsible for 50-60% of the PGE2 produced in response to inflammatory cytokines. In 
this study, we optimized an RNAi protocol and identified cPLA2a to be involved in 
approximately 100% of the PGE2 production in A549 cells stimulated with inflammatory 
cytokines. We also showed that cPLA2a, cPLA2y, cPLA2F, and iPLA2 may play roles in 
basal prostanoid synthesis, and that cPLA2P is not involved in the prostanoid synthetic 
pathway in A549 cells. The importance of these findings is as follows: First, cPLA2a has 
been confirmed as the major regulator of PGE2 synthesis in response to inflammatory 
cytokines in line with previously reported findings involving lipopolysaccharides (LPS) 
and calcium ionophore, A23 187. Second, siRNA targeting cPLA2a can be developed as a 
potential therapeutic agent against asthma. Finally, phospholipases may have 
implications as new drug targets against asthma, inflammation and cancer therapies. 
Initially, we spent approximately 8 months on optimizing the protocols that were 
used in this study. First, when we used DMEM to wash the cells prior to the transfection 
with siRNA, we observed that most of the cells in the center of the wells died just 24 
hours post-transfection. We were able to overcome this obstacle by replacing DMEM, 
which proved to be toxic to RNAi transfected cells, with Optimem and the cell survival 
rate increased dramatically. Next, we were using Oligofectamine transfection reagent 
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(Invitrogen) to introduce siRNA to A549 cells. This protocol, at first, produced a 
reproducible result, until the manufacturer changed the reagent and protocol for siRNA 
delivery, causing non-reproducible results. Thus, we examined Dharmafect, the RNAi 
transfection reagent manufactured by the same company that produces siRNA, and 
reproducible results were obtained from this reagent. Another obstacle that we overcame 
was the elevated basal levels of PGE2 production from the non-cytokine treated A549 
cells, which may have been due to over stressing the cells by transfection. We 
incorporated a washout step with A549 complete media 24 hours post-transfection to 
overcome the elevated basal PGE2 production. Finally, allowing for significant 
observations in cytokine response, an assay for RNAi use in examining PGE2 production 
was generated giving very reproducible results, which is now the "Gold standard used in 
the Chalfant laboratory. 
As aforementioned, unpublished studies from our laboratory demonstrated that 
cPLA2a may play a role in the production of 50-60% of PGE2 in A549 cells treated with 
inflammatory cytokines. This led to our initial hypothesis that the closely-related PLA2s, 
cPLA2P, cPLA2y, cPLA26, or iPLA2, may be responsible for the remaining 40-50% of the 
PGE2 production. By utilizing RNAi technology and down-regulating cPLA2a, we have 
demonstrated that cPLA2a actually is responsible for approximately 100% of the PGE2 
synthesized in response to treatment with cytokines. Furthermore, studies using 
osteoblastic bone marrow stromal cells from cPLA2a knockout mice indicated that 
cPLA2a played a key role in PGE2 production, in response to lipopolysaccharide (LPS) 
[24,31]. Our studies have similar effects on PGE2 production by cPLA2a in response to 
extracellular mediators. In addition, other PLA2 isoforms examined in this study had no 
involvement in cytokine mediated PGE2 synthesis. 
These individual PLA2 isoforms, cPLA2a, cPLA2y, cPLA26, and iPLA2, may be 
involved in basal prostanoid synthesis. In addition, this study revealed that down- 
regulation of cPLA2P did not have any significant change in the production of PGE2 in 
the presence or absence of cytokines. Thus, a function for cPLA2P is still elusive. 
The findings from this study are also important for several other reasons. First, 
understanding the individual enzymes involved in the cascade of steps leading to 
prostanoid synthesis following the envenomation of a brown recluse spider can result in a 
new treatment regiment to the spider bite. Furthermore, these findings may shed light to 
the mysterious recurrence of necrotic and hemolytic effects proximal to the brown recluse 
envenomation site several months after the bite. Second, these findings can lead to the 
development of siRNA as a potential therapeutic agent, in the form of an inhaler, against 
asthma. Finally, identification of the most important phospholipases in the prostanoid 
synthetic pathway can lead to new drug targets in treating asthma, inflammation and 
cancer. Thus, better understanding of the role of cPLA2a in the inflammatory pathway 
can lead to a new approach to bone disease by inhibiting cPLA2a, especially with the 
newly discovered cardiac risks associated with selective COX-2 inhibitors such as 
Celebrex and Vioxx. 
In conclusion, these results demonstrate cPLA2a as the phospholipase A2 
responsible for the PGE2 production in response to inflammatory cytokines. Furthermore, 
these results also demonstrate that cPLA2a, along with cPLA2y, cPLA26, and iPLA2 are 
all involved in basal prostanoid synthesis and that cPLA2P plays no part in the prostanoid 
synthetic pathway in the presence or absence of cytokines. These findings may have 
implications in better understanding the pathophysiology of a brown recluse spider bite, 
incorporating RNAi technology as a potential pharmacological tool, and giving rise to 
new targets for anti-asthma, anti-inflammatory and anti-cancer therapies. 
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